EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

HER2 becomes a novel survival biomarker for gastric cancer patients: a pooled analysis

Ji Cheng iD, Ming Cai, Guobin Wang, Kaixiong Tao

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241271913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 05.09.2024. Verfasst von Ji Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenu…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although anti-HER2 therapies have been widely used against gastric carcinoma, the prognostic significance of HER2 overexpression remains unclear. Previous studies failed to provide convincible evidence due to inconsistent HER2 evaluation criteria and heterogeneous clinical characteristics.

Objectives

To figure out the prognostic significance of HER2 expression in gastric cancer, we rigorously designed and conducted this study.

Design

Meta-analysis. Data sources and methods: Record retrieval was performed by searching PubMed, Web of Science, Cochrane Library, Embase, ASCO, and ESMO meeting libraries from inception to November 2022. Cohort studies investigating overall survival comparison between HER2-positive and HER2-negative gastric cancer patients were included. Both resectable and advanced cases were separately collected while HER2 evaluation standards should be consistent across eligible studies. Newcastle–Ottawa Scale was used for quality assessment. Overall survival was the only endpoint and effect size was presented by hazard ratio (HR) with its 95% confidence interval. The pooled calculation was conducted on Review Manager 5.4.

Results

Thirty studies were eligible, including 9945 patients. Eligible studies were mostly high quality ( n = 31). Regarding resectable cases ( n = 22), HER2-positive groups had significantly worse prognosis than HER2-negative counterparts (HR 1.56, 95%CI 1.32–1.85, p < 0.00001). For HER2-positive patients with advanced gastric cancer ( n = 10), HER2 overexpression was also an unfavorable survival indicator (HR 1.70, 95%CI 1.23–2.35, p = 0.001). Potential heterogeneous studies had been eliminated while outcomes remained stable by sensitivity analysis. Subgroup analysis suggested HER2-positive patients had a poorer prognosis in both East Asian (resectable: HR 1.56; advanced: HR 1.32) and non-East Asian countries (HR 1.58; HR 3.27).

Conclusion

As a novel survival biomarker in gastric cancer, HER2 overexpression indicates unfavorable prognosis among both resectable and advanced patients, irrespective of East Asian or non-East Asian populations.

Trial registration

PROSPERO (CRD42020168051).

Schlagwörter

Stichwörter der Autor:innen

HER2gastric cancermeta-analysissurvivalsystematic review

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, China.
  • Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Ji Cheng

Förderung

  • Natural Science Foundation of Hubei Province

Zitieren

APA

Cheng, J., Cai, M., Wang, G., & Tao, K. (2024). HER2 becomes a novel survival biomarker for gastric cancer patients: a pooled analysis. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241271913

Vancouver

Cheng J, Cai M, Wang G, Tao K. HER2 becomes a novel survival biomarker for gastric cancer patients: a pooled analysis. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241271913

BibTeX
@article{Cheng2024,
  author = {Cheng, Ji and Cai, Ming and Wang, Guobin and Tao, Kaixiong},
  title = {HER2 becomes a novel survival biomarker for gastric cancer patients: a pooled analysis},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241271913}
}
Kostenlos starten →